Recall: D-0110-2027
Class II - Potentially Harmful
Class IIClassification
2026-10-06Initiated
OngoingStatus
Brandywine Pharmaceuticals, LLFirm
Product
Theophylline Extended-Release Tablets, 100 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-500-10
Reason
CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory
Distribution
Nationwide within U.S
Source: FDA drug enforcement report via openFDA (Voluntary: Firm initiated). If you take this product, talk to your pharmacist or doctor before stopping it.